Quick answer: peptide access rights in the U.S. are narrower than many people expect. When a peptide is unapproved or restricted, the lawful routes are: joining a clinical trial, FDA expanded access (21 CFR 312 subpart I), the federal Right to Try Act of 2018, a prescription for a compounded product where federal and state law allow that substance, and influencing policy through citizen petitions and public comments.[1][3][7] Right to Try and expanded access only apply to investigational drugs for serious or life-threatening conditions, so they rarely fit popular research peptides.
This guide covers each route, who qualifies and its limits. For background, see our FDA and regulation hub.
Summary of your options
| Route | Who can use it | Fits most “research peptides”? |
|---|---|---|
| Clinical trial | Anyone who meets a study’s eligibility criteria | Only if a trial exists |
| Expanded access | Serious or immediately life-threatening condition, no comparable alternative | Rarely; needs an investigational drug with a sponsor |
| Right to Try | Life-threatening condition, approved options exhausted | Rarely; needs Phase 1 completed and an active IND |
| Compounding by prescription | Patients whose clinician prescribes a lawful compounded drug | Depends on the substance’s FDA bulks status and state law |
| Citizen petition and public comment | Anyone | Yes; this is how policy changes |
1. Clinical trials
A trial is the most direct legal way to receive an unapproved peptide. Trials run under an Investigational New Drug application, with informed consent and review by an institutional review board. Our guide to peptide clinical trial regulation explains how they work.
You can search ClinicalTrials.gov by peptide name. For example, a University of Arkansas pilot trial of BPC-157 injections after rotator cuff surgery is registered as an FDA-regulated drug study; it was listed as not yet recruiting in September 2026.[10] Check eligibility, location and whether a placebo is used before contacting a study team.
2. Expanded access (compassionate use)
Expanded access is set out in 21 CFR 312, subpart I (sections 312.300 to 312.320). FDA must determine that:[3]
- the patient has a serious or immediately life-threatening disease or condition with no comparable or satisfactory alternative therapy;
- the potential benefit justifies the potential risks; and
- providing the drug will not interfere with trials that could support approval.
There are three types: individual patients, including emergencies (312.310); intermediate-size populations (312.315); and treatment INDs or protocols for large groups (312.320).[3] For an individual patient, the physician must judge that the drug’s probable risk is not greater than the disease’s, and FDA must find the patient cannot get the drug through another IND.[3]
Key practical limits:
- The drug company must agree to provide the drug; FDA cannot force it.
- A licensed physician has to make the request and take responsibility for treatment.
- For emergencies, FDA lists phone contacts, including an after-hours emergency line.[4]
Expanded access is designed for products in development, such as an experimental cancer peptide. It is not a route to products that no company is developing.
3. The Right to Try Act
The federal Right to Try Act, Public Law 115-176, was signed on May 30, 2018.[2] FDA describes the eligibility rules:[1]
Patient: diagnosed with a life-threatening disease or condition, has exhausted approved treatments and cannot join a trial of the drug (certified by a physician), and gives written informed consent.
Drug: has completed a Phase 1 trial, is not approved for any use, is the subject of an application or an adequate and well-controlled trial meant to support approval and an active IND, and is in active development or production.
FDA’s role is limited to receiving and posting certain information; it does not review individual Right to Try requests, and IRB approval is not required for them.[1] Manufacturers are not required to provide drugs. In a 2022 interview study of 17 neuro-oncologists, most were confused about the difference between the two pathways, knew little about Right to Try, and preferred enrolling patients in clinical trials.[11]
4. Compounding by prescription, where lawful
Compounding lets a pharmacist prepare a drug for an individual patient. Under section 503A of the FD&C Act, a licensed pharmacist or physician compounds based on a prescription for an identified patient, and bulk ingredients must meet federal criteria, such as having a USP monograph, being part of an approved drug, or appearing on FDA’s 503A bulks list.[7] 503B outsourcing facilities follow a separate set of rules.
For peptides without monographs, FDA’s interim categories matter. Category 1 substances may be compounded under FDA’s enforcement policy; Category 2 substances raise significant safety risks; Category 3 lacks enough information.[9] On April 15, 2026, FDA announced removal of 12 peptides from Category 2 after their nominators withdrew them. Law-firm analyses noted this did not by itself place them on the 503A list or in Category 1.[8]
FDA’s Pharmacy Compounding Advisory Committee then met July 23-24, 2026 to review BPC-157, KPV, TB-500 and MOTS-c on day one, and emideltide (DSIP), Semax and epitalon on day two.[6] News reports said the committee voted 8-6, with one abstention, to recommend adding BPC-157 to the 503A list,[12] but FDA’s meeting page had not posted vote results when we checked. A committee vote is advice. FDA must still decide and go through rulemaking.
State pharmacy and medical boards add their own limits. See 503A vs 503B compounding, state medical board rules on peptide therapy and telehealth peptide prescriptions.
5. Citizen petitions
Any person can ask FDA to issue, amend or revoke a regulation or take other action by filing a citizen petition under 21 CFR 10.30. Petitions go to FDA’s Dockets Management Staff and get a unique docket number. FDA must respond within 180 days, by approving, denying, or giving a tentative response explaining why it has not decided.[5]
Petitions work best when they are specific, cite evidence and request an action FDA has authority to take, such as reconsidering a substance’s compounding category.
6. Commenting on dockets and advisory committees
You can also influence peptide policy by:
- Commenting on FDA dockets at Regulations.gov for proposed rules, draft guidance and Federal Register notices. FDA must consider comments submitted to rulemaking dockets.
- Speaking or submitting comments for advisory committees. Committee meetings, including the PCAC, are announced in the Federal Register with a docket and usually include an open public hearing.[6]
- Contacting state boards when they consider peptide policies.
Comments that cite published evidence, describe real patient experience, and address the specific question asked are the most useful to reviewers.
What isn’t an access right
- Buying research use only peptides for self-injection is not a lawful route.
- Importing unapproved drugs for personal use is generally prohibited, with narrow enforcement discretion; see our guide to online peptide sales legal risks.
- A doctor’s note does not make an unapproved product legal to sell.
For the current status of specific compounds, see are peptides legal? and FDA peptide ban 2026.
This is general information, not legal advice. Eligibility rules and FDA’s compounding categories change, so confirm current details with FDA, your clinician or a lawyer.
